New diagnostic criteria for multiple sclerosis are helping doctors identify the disease sooner, allowing patients to begin ...

Dr. Daniel Ontaneda, a neurologist with Cleveland Clinic, said more than two dozen approved medications can help control MS ...

Our latest CPD module explores five common but challenging neurology cases encountered in general practice, and discusses evidence-based approaches to assessment, investigation and management.

Dysphagia, a severe comorbidity of many neurological diseases, often lacks targeted therapies. This critical review assessed ...

True disruption demands both vision and courage, and these ten remarkable women are leading that charge in 2026.

The plan's most telling feature is what it left out. Two months before the announcement, Pfizer and Valneva reported that their Lyme vaccine had passed its final major trial, cutting confirmed cases ...

A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B ...

Why does multiple sclerosis progress quickly in some people, while others remain stable for years? Researchers from the ...

An experimental MS therapy given as a nasal spray has started dosing its final participant in a Phase 2a trial of people with ...

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low ...

Increasing the Ocrevus dose used in treating MS provided no additional benefit versus the approved regimen in trials with over 1,500 patients.

Rituximab and ocrelizumab go head to head in randomized trial ...